PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

25 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

11 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

28 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

09 авг 2023 16:03:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

09 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

23 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

24 май 2023 08:00:01 Источник Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

10 май 2023 08:05:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

09 май 2023 16:02:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

30 апр 2023 14:10:28 Источник Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

12 апр 2023 08:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

27 мар 2023 08:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

13 мар 2023 08:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

09 мар 2023 16:05:01 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

08 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

01 мар 2023 08:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

07 фев 2023 08:01:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

02 фев 2023 08:02:00 Источник Nasdaq GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

27 янв 2023 16:03:00 Источник Nasdaq GlobeNewswire